Better patient outcomes at scale
start with better home care.

DSOs compete on clinical quality, patient retention, and operational efficiency — all three driven by the same upstream variable: what patients do at home.

Great Gums is the first clinically validated home care tool built around bioelectric disruption of gingival biofilm, with measurable improvements in inflammation, bleeding, and plaque across a 4-week RCT.

Clinically Proven Results

50.8%reduction in gum inflammation

64.2%reduction in bleeding on probing

17.9%reduction in plaque

We're building partnerships with DSOs who want to be early movers on a clinically differentiated product. Fill out the form and we'll ship you a brush before we talk.

Get in Touch & Try Our Brush

Fill out the form below and our team will follow up directly.

The business case

Why DSOs are the right partner for this category

The home care recommendation is one of the most consistent touchpoints a dental practice has with every patient. DSOs have the scale to make that recommendation mean something at a population level, and the operational infrastructure to implement it consistently.

Patient retention

Patients with healthier tissue between visits need fewer urgent appointments, have better recall compliance, and are more likely to refer. Home care quality is a retention lever.

Revenue per patient

A clinically credentialed retail recommendation at the point of care is a meaningful attach opportunity. DSOs with a standardized home care protocol capture value that currently walks out the door.

Clinical quality metrics

Payors and value-based care programs increasingly tie reimbursement to outcome metrics. A product that demonstrably improves gingival health scores across a patient population has direct clinical quality implications.

Standardization advantage

Independent practices can't implement a standardized home care protocol. DSOs can. That structural advantage compounds when the product is clinically differentiated and the recommendation is consistent across every location.

Early mover positioning

Bioelectric home care is a nascent category. DSOs that establish a partnership now are positioned to be associated with the clinical innovation rather than catching up to it.

Clinically credible recommendation

Great Gums is backed by a peer-reviewed IRB-approved RCT conducted at Ulsan University Hospital with advisors from Columbia University College of Dental Medicine. The recommendation stands up to clinical scrutiny.

The technology

A product your clinical team will stand behind and your patients will notice

Harmful bacterial biofilm accumulates at and below the gumline in the gingival sulcus, an area that bristle motion alone cannot reliably reach. It re-establishes within 24 to 48 hours of a professional cleaning, regardless of what brush a patient uses.

Great Gums uses patented bioelectric technology to disrupt biofilm at the sulcular level, producing measurable improvements in the clinical endpoints your providers record at every recall visit. Patients feel the difference. Providers see it.

Clinical evidence

The data your clinical leadership will want to see

4-week controlled trial versus manual and sonic brush controls. Every measured endpoint improved.

Study details

Study typePeer-reviewed IRB-approved RCT

SiteUlsan University Hospital

IRBNo. 2025-04-036

Duration4 weeks

Participants99

ControlsManual and sonic brushes

EndpointsGI, BOP, Plaque Index

Read the full report

Researchers & Advisors

Dr. Luiz A. Pimenta

Professor of Prosthodontics, Columbia University College of Dental Medicine

Internationally recognized for dental biomaterials research. Author of more than 100 peer-reviewed manuscripts with over 30 years of clinical experience.